TOP2B

Across TCGA pan-cancer cohorts, TOP2B mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of TOP2B’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TOP2B mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types TOP2B is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

CCRCC, COAD, and LSCC are the cancer types where TOP2B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TOP2B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	−0.350	<.001	12	view →
COAD	Male	III,IV	+0.401	<.001	10	view →
LSCC	Male	All	+0.405	<.001	9	view →
LUAD	Male	All	+0.253	<.001	7	view →
PDAC	All	All	+0.163	.011	4	view →
OV	All	All	+0.557	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

TOP2B–CCRCC

Open the CCRCC breakdown →